Elevation Point Wealth Partners LLC Has $2.15 Million Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Elevation Point Wealth Partners LLC grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 93.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 167,807 shares of the company’s stock after buying an additional 81,234 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Intellia Therapeutics were worth $2,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of NTLA. Comerica Bank boosted its position in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the period. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics in the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd bought a new stake in Intellia Therapeutics in the 3rd quarter valued at about $30,000. Advisory Services Network LLC bought a new stake in Intellia Therapeutics in the 3rd quarter valued at about $33,000. Finally, Spire Wealth Management acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $17.56 on Monday. The business has a fifty day moving average price of $14.13 and a two-hundred day moving average price of $13.07. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The stock has a market capitalization of $2.45 billion, a PE ratio of -4.96 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter last year, the company posted ($1.10) EPS. As a group, sell-side analysts expect that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. New Street Research set a $25.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. Sanford C. Bernstein increased their price target on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Chardan Capital raised their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. The Goldman Sachs Group lifted their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.46.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.